ECP 2022 Final Programme

Monday, 5 Sept Scientific Programme a Monday 43 ECP 2022 Basel 008 11:42–12:00 Case 8 Joze Pizem, Slovenia OFP-05 Oral Free Paper Session 08:30–12:00 Osaka/Samarkand Joint Oral Free Paper Session Uropathol- ogy / Nephropathology Chairs: Felix Bremmer, Germany Maike Büttner-Herold, Germany 001 08:30–08:40 Outcomes according to consensus molecular subtypes of urothelial carcinoma after neoadjuvant chemotherapy in the GETUG-AFU V05 VESPER trial Yves Allory, France C. S. Groeneveld, V. Harter, C. Krucker, V. Dixon, A. de Reynies, S. Culine, C. Pfister, F. Radvanyi 002 08:40–08:50 Clinicopathologic and molecular spectrum of testicular sex-cord stromal tumours not amenable to specific histopathologic subclassification Stephanie Siegmund, USA H. Tsai, I. Tran, Y. Yang, V. Vasudevaraja, M. Snuderl, K. Cornejo, M. Idrees, K. Al- Obaidy, K. Collins, J. Gordetsky, S. Wobker, K. Trpkov, A. Yilmaz, G. Quiroga-Garza, W. Anderson, M. Hirsch, C. Magi-Galluzzi, A. Acosta 003 08:50–09:00 Defining lineage plasticity in androgen indifferent prostate cancer Souzana Logotheti, Greece H. Vundavilli, M. Estecio, R. Soundararajan, P. Shepherd, J. Dong, A. Hoang, S. Guo, N. Navone, V. Tzelepi, C. Logothetis, Y. Lu, W. Wang, A. Aparicio 004 09:00–09:10 RNA-seq profiling of upper tract urothelial carcinoma: relevance of the bladder cancer consensus molecular classification, molecular heterogeneity and differential immune signatures Jacqueline Fontugne, France E. Xylinas, C. Krucker, V. Dixon, C. S. Groeneveld, H. Pinar, G. Califano, M. Bucau, J. Verine, F. Desgrandchamps, J. Hermieu, F. Radvanyi, Y. Allory, A. Masson- Lecomte 005 09:10–09:20 Spatial interplay between TIM3+, PD-L1+, PD-1+ and CLTA-4+ immune/ tumour cells using 18+1 BLEACH&STAIN mfIHC in more than 5 000 tissue samples Niclas Blessin, Germany N. F. Debatin, E. Bady, J. Müller, T. Mandelkow, M. Lurati, R. Simon, C. Hube-Magg 006 09:20–09:30 Successful deployment of an AI solution for prostate biopsies diagnosis in clinical practice Oleg Sukmanov, Israel A. Yosepovich, S. Ish – Shalom, S. Ikher, N. Ziv-Sokolovski, N. Temper, R. Ziv, I. Krasnitsky, I. Yazbin, G. Mallel, M. Grinwald, C. Linhart, M. Vecsler 007 10:30–10:40 The new entities LOT and EVT among oncocytic tumours of the kidney: a retrospective mono-institutional experience with re-analysis of 16 cases Alessandra Bressan, Italy P. Colombo, M. Valeri, M. Cieri, G. Elefante, S. Pancetti, V. Belsito, L. Terracciano, R. Hurle, M. Lazzeri, P. Casale 008 10:40–10:50 A novel pT1 substaging system for high-grade urothelial bladder carcinoma: a prospective mono-institutional confirmatory progression risk analysis Marina Valeri, Italy R. Contieri, V. Fasulo, M. Cieri, G. Elefante, C. De Carlo, A. Bressan, C. Saitta, A. Gobbo, P. Avolio, R. Hurle, M. Lazzeri, G. Taverna, L. Terracciano, P. Colombo 009 10:50–11:00 Computational analysis of nuclear features as a grading tool for urothelial carcinoma Ibrahim Fahoum, Israel D. Rattner, A. Zubkov, A. Greenberg, O. Greenberg, R. Naamneh, V. Zemser- Werner, S. Tsuriel, R. Hagege, D. Hershkovitz